The Australian Medicines Agency (TGA) announced the recognition of Coxing Vaccines in China and Covishield Covid-19 Vaccines in India, paving the way for overseas tourists and students who have been vaccinated with these two vaccines to enter Australia. Australian Prime Minister Scott Morrison said on the same day that the TGA released preliminary evaluation data for China’s Coxing Coronavac vaccine and India’s Covishield vaccine (actually the AstraZeneca vaccine produced in India), and suggested that these two vaccines should be listed as “recognized.” Vaccine”. As Australia’s national vaccination rate approaches the critical threshold of 80%, the country has begun to lift some of the world’s strictest border restrictions on the epidemic, and plans to open its international borders in November. In addition to the two newly approved vaccines, the current TGA approved vaccines include Pfizer/BioNTech vaccine (Comirnaty), AstraZeneca vaccine (Vaxzevria), Modena vaccine (Spikevax) and Johnson & Johnson’s Janssen vaccine.
However, it is important to note that being listed as an “accepted vaccine” does not mean that it is approved for vaccination in Australia, and the two are regulated separately.The TGA has not approved either vaccine for use in Australia, although the Vaccine has been certified for emergency use by the World Health Organisation.
This is similar to some other countries in Europe and the US.In late September, the United States announced that all people who received vaccines certified by the World Health Organization for emergency use would be considered “fully vaccinated” and allowed to enter the Country.This means that foreign passengers vaccinated with Sinovac, Sinopharm and other Chinese vaccines that have been included in the WHO’s list of emergency use can enter the United States after showing proof of “full vaccination” and a negative nucleic acid report within 3 days before boarding the plane.
In addition, the TGA has assessed six vaccines, but four others have not yet been “recognized” due to insufficient data available, according to the statement.
They are:Bibp-corv, developed by Sinopharmacy of China; Convidecia, made by China’s Convidecia; Covaxin, made by Bharat Biotech of India; and Gamaleya of RussiaSputnik V, developed by the Institute.
Regardless, Friday’s decision could open the door to thousands of foreign students who have been turned away from Australia during the pandemic.International education is a lucrative source of revenue for Australia, raking in a $14.6 billion ($11 billion) in 2019 in New South Wales alone.
More than 57,000 students are estimated to be overseas, according to the NSW government.Chinese nationals are the largest source of international students in Australia, followed by India, Nepal and Vietnam, according to trade department data.
Post time: Nov-18-2021